Nicolas Boisgerault

A novel tumor-targeted interferon-α/-β receptor 1 antagonist increases replication of oncolytic vesicular stomatitis virus in a mouse mesothelioma model

This paper develops IFNAR1 antagonists that selectively block IFNAR signaling in tumor cells, enhancing VSV oncolytic activity in mesothelioma and melanoma models.

Oncolytic measles virus reprograms the tumor microenvironment in a vascularized mesothelioma-on-chip model

This study develops a vascularized mesothelioma-on-chip model to evaluate oncolytic measles virus effects on the tumor microenvironment.

In vitro models to mimic tumor endothelial cell-mediated immune cell reprogramming in lung adenocarcinoma

This study investigates how NSCLC cells reprogram endothelial cells into tumor endothelial cells, altering immune cell behavior in vitro.

Disabling a key viral innate immunity antagonist converts measles vaccine into RIG-I-driven cancer immunotherapy

This paper modifies a measles vaccine by removing a viral protein to create a cancer immunotherapy that activates the immune system via RIG-I signaling, leading to tumor regression in multiple models.